Oxford Nanopore Technologies and Geneyx Announce the First Scalable Software Solution to Advance the Future Clinical Use of Nanopore Sequencing
Summary
The advanced platform will seamlessly empower clinical centres including hospitals, genetic labs and researchers with human whole-genome sequencing data and analysis. Once available, it will be of immediate use in newborn screening and the research and characterisation of rare and undiagnosed diseases, providing “one-click” analysis of whole human sequencing data, including actionable genetic variants. The results will then be pushed to the Geneyx cloud and on-site capability, where precise annotation and classification of the variants will be performed, providing a further layer of simplified bioinformatics designed for future clinical use. Through this seamless integration, customers will benefit from the combined power of nanopore sequencing with Geneyx’s AI-powered analysis for an added layers of insight to support critical workflows such as newborn screening and research into rare disease.” "This collaboration combines Geneyx’s analysis expertise with Oxford Nanopore Technologies groundbreaking sequencing technology. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA.
Classifications
AskAI Classifications
LabelsLinked Companies
